Abstract
Background
Bacteria and viruses have been implicated as a major cause of chronic obstructive pulmonary disease (COPD) exacerbations; however, the potential role of fungal colonization and infection is poorly understood.
Objective
The aim of this study was to assess the profile of pulmonary fungal infection among COPD patients with and without comorbidities to determine their prevalence, risk factors, and outcome among those patients.
Patients and methods
In this prospective cross-sectional analytic study, different samples (sputum, bronchoalveolar lavage, blood, and others) from 177 COPD patients at risk for pulmonary fungal infection were examined using mycological analysis (direct microscopy and culture). Bronchoalveolar lavage and blood samples were examined using the human 1,3-β-D-glucan and galactomannan ELISA tests.
Results
The prevalence of pulmonary fungal infection was significantly higher in COPD patients with comorbidities (77.8%) versus COPD patients without comorbidities (53.1%) (P <0.001), with a predominance of Candida and Aspergillus spp. in both groups. Mechanical ventilation, corticosteroid therapy, ICU admission, and age were major risk factors for pulmonary fungal infection in COPD patients with comorbidities [P=0.012, odds ratio (ODR)=2.23; P=0.028, ODR=1.99; P=0.025, ODR=1.94; and P=0.034, ODR= 2.60; respectively]. COPD patients with comorbidities had significantly higher mortality rate (12.3%) compared with COPD patients without comorbidities (3.1%; P <0.05). Blood galactomannan antigen was positive in 16 (19.7%) COPD patients with comorbidities versus seven (7.3%) in COPD patients without comorbidities (P <0.05).
Conclusion
COPD patients with comorbidities had a higher prevalence of pulmonary fungal infection and higher mortality rate compared with COPD patients without comorbidities. Age, mechanical ventilation, corticosteroid therapy, and ICU admission were independent risk factors for pulmonary fungal infection in COPD patients with comorbidities.
Article PDF
Similar content being viewed by others
References
Putcha N, Puhan MA, Hansel NN, Drummond MB, Boyd CM. Impact of comorbidities on self-rated health in self-reported COPD: an analysis of NHANES 2001–2008. COPD 2013; 10:324–332.
Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186:155–161.
Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359:2355–2365.
O’Donnell R, Breen D, Wilson S, Djukanovic R. Inflammatory cells in the airways in COPD. Thorax 2006; 61:448–454.
Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J 2007; 30:782–800.
Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay:ameta-analysis. Clin Infect Dis 2006; 42:1417–1427.
Dutkiewicz R, Hage CA. Aspergillus infections in the critically ill. Proc Am Thorac Soc 2010; 7:204–209.
Garnacho-Montero J, Olaechea P, Alvarez-Lerma F, Alvarez-Rocha L, Blanquer J, Galván B, et al. Epidemiology, diagnosis and treatment of fungal respiratory infections in the critically ill patient. Rev Esp Quimioter 2013; 26:173–188.
Xavier MO, Oliveira FdM, Severo LC. Chapter 1: laboratory diagnosis of pulmonary mycoses. J Bras Pneumol 2009; 35:907–919.
Wright WF, Overman SB, Ribes JA. (1-3)-β-d-Glucan assay: a review of its laboratory and clinical application. Lab Med 2011; 42:679–685.
Du Rand IA, Blaikley J, Booton R, Chaudhuri N, Gupta V, Khalid S, et al. British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE. Thorax 2013; 68(Suppl 1):i1–i44.
Jourdain B, Joly-Guillou ML, Dombret MC, Calvat S, Trouillet JL, Gibert C, Chastre J. Usefulness of quantitative cultures of BAL fluid for diagnosing nosocomial pneumonia in ventilated patients. Chest 1997; 111:411–418.
Stynen D, Goris A, Sarfati J, Latgé JP. A new sensitive sandwich enzymelinked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis. J Clin Microbiol 1995; 33:497–500.
Latgé JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999; 12:310–350.
Putcha N, Han MK, Martinez CH, Foreman MG, Anzueto AR, Casaburi R, et al. Comorbidities of COPD have a major impact on clinical outcomes, particularly in African Americans. Chronic Obstr Pulm Dis (Miami) 2014; 1:105–114.
Dal Negro RW, Bonadiman L, Turco P. Prevalence of different comorbidities in COPD patients by gender and GOLD stage. Multidiscip Respir Med 2015; 10:24.
Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007; 45:205–216.
Názara Otero CA, Baloira Villar A. The continuum of COPD and cardiovascular risk: a global scenario of disease. Clin Investig Arterioscler 2015; 27:144–147.
MacNee W, Rabinovich RA, Choudhury G. Ageing and the border between health and disease. Eur Respir J 2014; 44:1332–1352.
Jo YS, Choi SM, Lee J, Park YS, Lee SM, Yim JJ, et al. The relationship between chronic obstructive pulmonary disease and comorbidities: a cross-sectional study using data from KNHANES 2010–2012. Respir Med 2015; 109:96–104.
Miravitlles M, Price D, Rabe KF, Schmidt H, Metzdorf N, Celli B. Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2015; 10:549–564.
Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004; 170:621–625.
Tutar N, Metan G, Koç AN, Yilmaz I, Bozkurt I, Simsek ZO, et al. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Multidiscip Respir Med 2013; 8:1–7.
Ader F, Nseir S, Le Berre R, Leroy S, Tillie-Leblond I, Marquette CH, Durocher A. Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogen. Clin Microbiol Infect 2005; 11:427–429.
Agustí C, Rañó A, Filella X, González J, Moreno A, Xaubet A, Torres A. Pulmonary infiltrates inpatients receivinglong-termglucocorticoid treatment: etiology, prognostic factors, and associated inflammatory response. Chest 2003; 123:488–498.
Guinea J, Torres-Narbona M, Gijón P, Muñoz P, Pozo F, Peláez T, et al. Pulmonaryaspergillosisinpatientswithchronicobstructivepulmonarydisease: incidence, risk factors, and outcome. Clin Microbiol Infect 2010; 16:870–877.
Leav BA, Fanburg B, Hadley S. Invasive pulmonary aspergillosis associated with high-dose inhaled fluticasone. N Engl J Med 2000; 343:586.
Muquim A, Dial S, Menzies D. Invasive aspergillosis in patients with chronic obstructive pulmonary diseases. Can Respir J 2005; 12:199–204.
He H, Ding L, Li F, Zhan Q. Clinical features of invasive bronchialpulmonary aspergillosis in critically ill patients with chronic obstructive respiratory diseases: a prospective study. Crit Care 2011; 15:R5.
Perfect JR, Cox GM, Lee JY, Kauffman CA, de Repentigny L, Chapman SW, et al. The impact of culture isolation of Aspergillus species: a hospitalbased survey of aspergillosis. Clin Infect Dis 2001; 33:1824–1833.
Author information
Authors and Affiliations
Corresponding author
Additional information
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Mohamed, A.Z., Moharrm, A.M., Ghanem, M.K. et al. Role of comorbidities in acquiring pulmonary fungal infection in chronic obstructive pulmonary disease patients. Egypt J Bronchol 10, 243–250 (2016). https://doi.org/10.4103/1687-8426.193629
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.4103/1687-8426.193629